Alpha Profiles · Company Profile

Cue Biopharma, Inc.

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/cue-biopharma-inc

Entity: Public listing published
Primary listing: NASDAQ: CUE
Verification: Partially verified
Last reviewed: 2026-09-13T04:46:38.603185+00:00

Overview

Alpha's canonical identity and public leadership record for Cue Biopharma, Inc..

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

4 public records

Colin G. Sandercock

Senior Vice President, General Counsel and Secretary

State: confirmed
Effective: From Mar 16, 2026
Confidence: 94%
Evidence: CUE DEF 14A executive officersMar 16, 2026

Douglas G. Baker

Interim Chief Development Officer

State: confirmed
Effective: From Mar 16, 2026
Confidence: 94%
Evidence: CUE DEF 14A executive officersMar 16, 2026

Lucinda Warren

Chief Financial and Business Officer

State: confirmed
Effective: From Mar 16, 2026
Confidence: 94%
Evidence: CUE DEF 14A executive officersMar 16, 2026

Usman Azam

President, Chief Executive Officer and Director

State: confirmed
Effective: From Mar 16, 2026
Confidence: 94%
Evidence: CUE DEF 14A executive officersMar 16, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 13, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.